BeiGene (BGNE)
(Delayed Data from NSDQ)
$156.36 USD
-1.24 (-0.79%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $156.60 +0.24 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BGNE 156.36 -1.24(-0.79%)
Will BGNE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BGNE
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
Top 5 Momentum Picks for January After a Fabulous 2023
New Strong Buy Stocks for December 22nd
Other News for BGNE
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Immunocore Holdings (IMCR) and COMPASS Pathways (CMPS)
7 Large-Cap Stocks That Can Jump 50% By 2025
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment